-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$6.67437.9% Upside
Lyell Immunopharma, Inc. Frequently Asked Questions
-
What analysts cover Lyell Immunopharma, Inc.?
Lyell Immunopharma, Inc. has been rated by research analysts at Bank of America Securities, Morgan Stanley, Goldman Sachs in the past 90 days.